On this page
-
Outcomes for both multidrug-resistant (MDR) and non-MDR tuberculosis cases in NSW, 2023
-
Contact investigation outcomes from tuberculosis pulmonary smear positive cases diagnosed in NSW, 2023
Outcomes for both multidrug-resistant (MDR) and non-MDR tuberculosis cases in NSW, 2022
The majority of TB cases successfully completed TB treatment in 2022 (90%). The treatment outcome is unable to be assessed when people transfer overseas (3% of cases), and a small number of cases die from causes not related to TB while on treatment (4% of cases).
| Completed treatment | 478 (90%) | 8 (89%) |
|---|
| Defaulted | 7 (1%) | 0 (0%) |
|---|
| Treatment failure | 1 (<1%) | 0 (0%) |
|---|
| Died due to TB | 3 (1%) | 1 (11%) |
|---|
| Died of other or unknown causes | 21 (4%) | 0 (0%) |
|---|
| Transferred overseas to complete treatment | 16 (3%) | 0 (0%) |
|---|
| Remains on extensive treatment | 3 (1%) | 0 (0%) |
|---|
Contact investigation outcomes from TB pulmonary smear positive cases diagnosed in NSW, 2023
There were 1724 contacts identified in NSW in 2023 from TB pulmonary smear positive cases, 62% of those completed contact screening for TB.
Notes
Data for this report was extracted from Notifiable Conditions Records for Epidemiology and Surveillance, NSW Ministry of Health on 24 September 2024.
Laboratory
2023 report
Past reports
